▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (FDA approved April 2023 for hematologic malignancies; December 2025 for severe aplastic anemia).
Omisirge omidubicel-onlv Updated Nov 3
What to watch
Omisirge is already FDA-approved with no pending regulatory binary for this drug. The key event for KPTI holders is the Chapter 11 court-supervised sale process (confirmation hearing January 11, 2027) and the proposed merger with Ayrmid closing in Q1 2027, but existing KPTI equity is expected to receive zero recovery.
Bull case
- Omisirge is the first FDA-approved allogeneic progenitor cell therapy for hematologic malignancies (April 2023) and the first cellular therapy for severe aplastic anemia (December 2025), addressing significant unmet needs.
- The drug is a nicotinamide-modified cord blood therapy that reduces time to neutrophil recovery and infection incidence after transplant, with a differentiated mechanism.
- Ayrmid (which owns Omisirge) has built a commercial platform with U.S. infrastructure and international distribution, and would bring Omisirge into the combined entity post-merger.
Bear case
- KPTI filed for Chapter 11 bankruptcy on November 2, 2026; existing common stock will be canceled with zero recovery, per the 8-K filing.
- Omisirge is not currently a Karyopharm asset; it is owned by Ayrmid Ltd./Gamida Cell, which is the merger partner, not the current KPTI entity.
- KPTI stock closed at $0.088 on November 3, 2026, down ~21%, with a market cap around $20M, reflecting the expected equity wipeout.